PDCD1 and metastatic colorectal cancer: Similarly, MSI was shown to be associated with the response to PD-1 treatments in solid tumors, such as metastatic colorectal cancer, and Keytruda was approved to treat MSI-high or mismatch repair-deficient patients with solid tumors (64–67).